Fujian Shengdi Pharmaceutical Co., Ltd.

This study is testing whether an investigational injection called HRS9531 can help control heart failure symptoms and reduce body weight in adults with obesity. About 200 participants with a specific type of heart failure were randomly assigned to receive either the real injectio…

This study aims to see if a new weekly injection called HRS9531 works as well or better than the established drug semaglutide for weight loss in adults with obesity. About 572 participants will receive one of the two injections for 52 weeks while researchers track changes in body…

This study is testing an investigational injection called HRS-5632 to see if it safely lowers high levels of a blood fat called lipoprotein(a), or Lp(a), which is linked to heart attack and stroke risk. It involves about 203 adults who are already at high risk for heart problems …